KUALA LUMPUR: Eighteen selected hospitals across the country have begun offering free Sofosbuvir-based direct-acting antiviral (DAA) therapy for treatment of Hepatitis C since early this month, according to Health Minister Datuk Seri Dr S. Subramaniam.
He said the first phase of the treatment was given to 2,000 chronic Hepatitis C patients ... Read More
Hepcasia Administrator
21
Sep2017
CL ends Gilead's dangerous games with lives of HepC patients in Malaysia
Result of hard fought efforts of community-based groups, NGOs and treatment providers
20 September 2017, Bangkok and Kuala Lumpur: The Asia-Pacific Network of People living with HIV (APN+) joins the Positive Malaysian Treatment Access and Advocacy Group (MTAAG) in welcoming the ... Read More
September 21, 2017Hepcasia Administrator
03
Aug2017
Ever since generic DAA made available in early 2015 with Gilead's VL to several Indian generic manufacturers, there has been some progress as well as challenges in the context of access to Hepatitis C treatment. During Asia Pacific AIDS and Co-infection conference in Hong Kong June 2017, Giten Khwahirakpam from ... Read More
August 3, 2017Hepcasia Administrator
15
Feb2017
A joint press release between I-MAK, DNP+ and MSF Access Campaign on challenges to patents (patent oppositions) was filed in India on key hep C drugs sofosbuvir, daclatasvir and velpatasvir.
New Delhi/New York, 14 February 2017–Five new challenges against patents on crucial new medicines to treat ... Read More
February 15, 2017Hepcasia Administrator
21
Dec2016
December 21, 2016Hepcasia Administrator
28
Jun2016
June 28, 2016Hepcasia Administrator
15
Jun2016
June 15, 2016Hepcasia Administrator
03
May2016
Download PDF
May 3, 2016Hepcasia Administrator